<DOC>
	<DOCNO>NCT01940133</DOCNO>
	<brief_summary>This study Phase I , open label study determine Maximum Tolerated Dose ( MTD ) Recommended Phase II Dose ( RP2D ) patient advance solid tumor .</brief_summary>
	<brief_title>A Study Investigate Safety , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) PQR309</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically confirm diagnosis advance solid tumor therapy proven efficacy available . Age â‰¥ 18 Evidence tumor progression measurable evaluable disease . Use adequate contraceptive measure male patient . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 01 . Signed informed consent . Concomitant anticancer therapy ( e.g. , chemotherapy , radiotherapy , hormonal , immunotherapy , biological response modifier , signal transduction inhibitor ) Patients history myocardial infarction coronary artery bypass within last 3 year . Patients severe/unstable angina , coronary/peripheral arterial bypass , symptomatic congestive heart failure NYHA Class 3 4 , hypertension BP &gt; 150/100mmHg . Prediagnosed diabetes mellitus . Fasting glucose &gt; 7.0 mmol/L HbA1c &gt; 6 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>